| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―Aug―26 |
Metabolism configures immune response across multi-systems: Lessons from COVID-19 |
Tinku Gupta, Dhanya Rajendran, Akash Gujaral, Ashok Jangra |
| 2 |
[GO] |
2023―May―23 |
Circulating ACE2 level and zinc/albumin ratio as potential biomarkers for a precision medicine approach to COVID-19 |
Serena Benedetti, Davide Sisti, Daniela Vandini, Simone Barocci, Maurizio Sudano, Eugenio Carlotti, et al. (+2) Jade Lee Lee Teng, Loris Zamai |
| 3 |
[GO] |
2022―Oct―17 |
Understanding the exceptional pre-vaccination Era East Asian COVID-19 outcomes |
Jay Bhattacharya, Phillip Magness, Martin Kulldorff |
| 4 |
[GO] |
2022―Oct―08 |
COVID-19 models and expectations - Learning from the pandemic |
John P.A. Ioannidis, Stephen H. Powis |
| 5 |
[GO] |
2022―Oct―01 |
A consensus of evidence: The role of SPI-M-O in the UK COVID-19 response |
Graham F. Medley |
| 6 |
[GO] |
2022―Sep―30 |
Virus spread on a scale-free network reproduces the Gompertz growth observed in isolated COVID-19 outbreaks |
Francesco Zonta, Michael Levitt |
| 7 |
[GO] |
2022―Sep―24 |
Why COVID-19 modelling of progression and prevention fails to translate to the real-world |
Carl J. Heneghan, Tom Jefferson |
| 8 |
[GO] |
2022―Jul―19 |
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial |
Leon Peto, Peter Horby, Martin Landray |
| 9 |
[GO] |
2021―Aug―16 |
COVID-19 from a pharmacological perspective |
Giuseppe Remuzzi |
| 10 |
[GO] |
2021―Aug―12 |
Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19? |
Mariele Montanari, Barbara Canonico, Evelyn Nordi, Daniela Vandini, Simone Barocci, Serena Benedetti, et al. (+2) Eugenio Carlotti, Loris Zamai |
| 11 |
[GO] |
2021―Jul―23 |
Thromboprophylaxis in COVID-19 - Rationale and considerations |
Sotirios Bristogiannis, Dawn Swan, Jecko Thachil |
| 12 |
[GO] |
2021―Jul―15 |
Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19 |
Emanuela Ricciotti, Krzysztof Laudanski, Garret A. FitzGerald |
| 13 |
[GO] |
2020―Jul―21 |
Where are we with understanding of COVID-19? |
Shaw M. Akula, James A. McCubrey |
| 14 |
[GO] |
2020―Jul―16 |
The clinical impact of COVID-19 epidemic in the hematologic setting |
Carlo Finelli, Sarah Parisi |
| 15 |
[GO] |
2020―Jul―09 |
Foreword for the special issue advances in COVID-19: Biology and clinic |
James A. McCubrey, Shaw M. Akula, Bernard Payrastre |
| 16 |
[GO] |
2020―Jul―04 |
Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression |
Günther Schönrich, Martin J. Raftery, Yvonne Samstag |
| 17 |
[GO] |
2020―Jun―26 |
Cancer therapy and treatments during COVID-19 era |
Shaw M. Akula, Stephen L. Abrams, Linda S. Steelman, Saverio Candido, Massimo Libra, Kvin Lerpiriyapong, et al. (+12) Lucio Cocco, Giulia Ramazzotti, Stefano Ratti, Matilde Y. Follo, Alberto M. Martelli, William L. Blalock, Manuela Piazzi, Giuseppe Montalto, Melchiorre Cervello, Monica Notarbartolo, Jorg Basecke, James A. McCubrey |
| 18 |
[GO] |
2020―Jun―20 |
Where are we with understanding of COVID-19? |
Shaw M. Akula, James A. McCubrey |
| 19 |
[GO] |
2020―Jun―17 |
Thromboembolic events and Covid-19 |
Agnès Ribes, Fanny Vardon-Bounes, Vincent Mémier, Michael Poette, Jonathan Au-Duong, Cédric Garcia, et al. (+5) Vincent Minville, Pierre Sié, Alessandra Bura-Rivière, Sophie Voisin, Bernard Payrastre |
| 20 |
[GO] |
2020―Jun―17 |
SARS-CoV-2 pandemic: An overview |
Cecilia Acuti Martellucci, Maria Elena Flacco, Rosaria Cappadona, Francesca Bravi, Lorenzo Mantovani, Lamberto Manzoli |
| 21 |
[GO] |
2020―Jun―13 |
NK cells: A double edge sword against SARS-CoV-2 |
Elena Masselli, Mauro Vaccarezza, Cecilia Carubbi, Giulia Pozzi, Valentina Presta, Prisco Mirandola, Marco Vitale |
